L. Donnelly (London, United Kingdom), G. Caramori (Ferrara, Italy)
Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma D. Singh, M. Hunter, L. Pearce Collins, M. Perkins, R. Pettipher, E. Townsend, S. Vinall, B. O‘Connor (Manchester, Oxford, London, United Kingdom)
| |
Effects of atorvastatin in asthmatic patients under treatment with high dose inhaled or oral steroid S. A. Alavi Foumani, F. Nejatifar, K. ForghanParast, S. Heidarinejad, G. Mortazhejri (Rasht, Islamic Republic Of Iran)
| |
Safety and efficacy of SCH527123, a novel CXCR2 antagonist, in patients with COPD H. Magnussen, O. Holz, H. Watz, M. Sauer, I. Khanskaya, L. Gann, P. Stryszak, H. Staudinger, J. Sadeh (Germany; Kenilworth, United States Of America)
| |
TPI ASM8 reduces eosinophil progenitor cells in sputum after allergen challenge in mild asthmatics H. Imaoka, R. Sehmi, R. Pageau, R. Sequin, P. Renzi, G. Gauvreau (Hamilton, Montreal, Canada)
| |
Efficacy and safety of AZD9668, an oral neutrophil elastase inhibitor, in idiopathic bronchiectasis N. Snell, R. Stockley, J. Perrett, K. Gunawardena (London, , Loughborough, United Kingdom)
| |
Oxygen therapy decreases systemic inflammation in patients with chronic obstructive pulmonary disease and hypoxemia P. Alexandre, S. Jaume, R. Angel, N. Aina, I. Amanda, A. Alvar (Palma de Mallorca, Bunyola, Spain)
| |
Safety profile and clinical activity of multiple subcutaneous (SC) doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in subjects with asthma C. Oh, J. Parker, G. Geba, N. Molfino (Gaithersburg, United States Of America)
| |
Effects of erdosteine on serum biomarker concentrations at COPD exacerbation B. Bianchi, M. Ballabio, M. Moretti (Carrara, Milano, Italy)
| |